Neautus raises HK$262m in Hong Kong IPO, 2,190 times oversubscribed
Sichuan Neautus raised about HK$262m on the Hong Kong Main Board, with its public offer tranche 2,190.99 times covered and shares priced at HK$40.20 each.
What happened
Sichuan Neautus Traditional Chinese Medicine listed on the Hong Kong Main Board on 11 November, raising about HK$262m from 6,517,300 H shares at HK$40.20 each. The public offering tranche was 2,190.99 times oversubscribed. GF Capital (Hong Kong) and ABCI Capital were joint sponsors.
The numbers
| Item | Figure |
|---|---|
| Gross proceeds | About HK$262m |
| Shares offered | 6,517,300 H shares |
| Offer price | HK$40.20 |
| Public tranche | 2,190.99 times covered |
| Revenue rank in decoction-ready TCM, 2025 | Second in China |
| Markets | Hong Kong, Taiwan, Vietnam, Malaysia |
Why it matters
Neautus makes decoction-ready TCM, the step between raw herbs and hospital dispensing. It is a scaled supplier with real revenue, and its distribution into Hong Kong, Taiwan, Vietnam and Malaysia gives it an export angle that most domestic TCM suppliers lack.
The counter-argument is that a 2,190-times retail book reflects a small float and hot money rather than institutional conviction, and TCM quality standards remain a regulatory risk. Even so, the listing shows Hong Kong will fund consumer-health stories with revenue, not only technology.
What to watch
- Post-debut price once the retail book clears.
- Use of proceeds for capacity expansion.
- Growth of Southeast Asian distribution into a material export business.
Original source: Kirkland & Ellis · 11 Nov 2026
